Trial Profile
Phase 2 Study of Orally Administrated JBM-TC4 for the Prevention of Acute Radiation-induced Dermatitis in Breast Cancer Patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2018
Price :
$35
*
At a glance
- Drugs JBM TC4 (Primary) ; PEG 400
- Indications Radiodermatitis
- Focus Therapeutic Use
- Sponsors Joben Bio-Medical
- 14 Jun 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016.
- 14 Jun 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Dec 2016.
- 25 Nov 2014 New trial record